Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2024 04:00 ET | Source: AKAMPION

selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis

- New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity ...
April 29, 2024 04:00 ET | Source: AKAMPION

selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis

si-544 was well tolerated with no serious adverse effects, dose limiting toxicities, or safety signals observed75% of patients receiving si-544 experienced objective clinical improvement, of which 44%...
January 05, 2024 04:00 ET | Source: AKAMPION

selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024

Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patientsPipeline molecule to treat T cell mediated autoimmune diseases San Diego, CA, USA, and...
May 30, 2023 04:00 ET | Source: AKAMPION

selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis

Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity Dosing of MAD stage has been initiated; first results expected for late...